The presence of soluble NKG2D ligands in the sera of cancer patients has been extensively documented, and their levels very often correlate with tumor stage and poor prognosis as well as downmodulation of NKG2D on NK and CD8+ lymphocytes (5, 6, 8–14). Here, KLRK1 is linked to neoplasm.